Pharmacological actions of sulodexide

Seminars in Thrombosis and Hemostasis

Volumn 24, Issue 2, 1998, Pages 127-138

  Ofosu, Frederick A ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Dermatan sulfates; Heparin; Profibrinolytic; Sulodexide

Indexed keywords

DERMATAN SULFATE; HEPARIN; SULODEXIDE;

ANTICOAGULATION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ACTIVITY; DRUG MECHANISM; HEART INFARCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MOLECULAR WEIGHT; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOSIS;

EID: 0031938089     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-995831     Document Type: Conference Paper

References (81)

1. Radhkrishnamurthy B, Ruia HA, Srinivanssan SR, Preau W, Falferes Jr ER, Berenson GS. Studies of the glycosaminoglycan composition and biologic activation of "Vessel." a hypolipedemic agent. Atherosclerosis 1978;31:217-229
2. Radhkrishnamurthy B, Sharmu C, Bhandaru RR, Berenson GS, Slanzani L, Mastacchi R. Studies of chemical and biologic properties of a fraction of Sulodexide, a heparin-like glycosaminoglycan. Atherosclerosis 1986;60:141-149
3. Salzman EW. Heparin for prophylaxis of venous thromboembolism. Ann NY Acad Sci 1989;556:371-377
4. Kakkar VV, Djazaeri B, Fok K, Gletcher M, Scully JG, Westwick J. Low molecular weight heparin and prevention of postoperative deep vein thrombosis. Br Med J 1982;284:375-374
5. Glazier RL, Crowell EB. Randomized prospective trial of continuous vs intermittent heparin therapy. JAMA 1976;236: 1365-1367
6. Boneu B, Buchanan MR, Cade JF, et al. Effects of heparin, its low molecular weight fractions and other glycosaminoglycans on thrombus growth in vivo. Thromb Res 1995;40:8-90
7. Buchanan MR, Boneu B, Ofosu FA, Hirsh J. The relative importance of thrombin inhibition and factor Xa inhibition to the antithromhotic effects of heparin. Blood 1995;65:198-201
8. Agnelli G, Cosmi B, Paola F, et al. A randomised double-blind placebo-controlled trial of dermatan sulphate for prevention of deep vein thrombosis in hip fracture. Thromb Haemostas 1992; 67:203-208
9. Lane DA, Ryan K, Ireland H, et al. Dermatan sulphate in hemodialysis. Lancet 1992;339:334-335
10. Condorelli M, Chiariello M, Dagianti A, et al. IPO-V2: A prospective, multicentre, randomized comparative clinical investigation of the effects of Sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction. Am J Coll Cardiol 1994;23:27-34
11. Doyle DJ, Turpie AGG, Hirsh J, et al. Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. Ann Intern Med 1987:107: 441-445
12. Hull R, Raskoh G, Rosenbloom D, et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 1992;152:1589-1595
13. Bachmann F, Leyvraz P-R. Low molecular weight heparins for prevention of venous thromboembolism following orthopedic surgery. In: Bounameaux H, ed. Low Molecular Weight Heparins in Prophylaxis and Therapy of Thromboembolic Diseases, New York, NY: Marcel Dekker; 1994:187-212
14. Locknen D. Low molecular weight heparins for treatment of established venous thromboembolism. In: Bounameaux H, ed. Low Molecular Weight Heparins in Prophylaxis and Therapy of Thromboembolic Diseases. New York, NY: Marcel Dekker; 1994:283-305
15. Rosenherg RD. The heparin-antithrombin system: A natural anticoagulant mechanism. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 3rd ed. Philadelphia, PA: Lippincott; 1994:837-860
16. Liu L, Dewar L, Song Y, et al. Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo. Thromb Haemostas 1995;73:405-412
17. Gouin-Thibault I, Dewar L, Kulczycky M, Sternbach M, Ofosu FA. Measurement of factor Xa-antithrombin III in plasma: Relationship to prothrombin activation in vivo. Br J Haematol 1995;90:669-680
18. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: Initiation, maintenance and regulation. Biochemistry 1991;30: 10363-10370
19. Rapaport SI. Rao L. Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler Throtmb 1992;12: 1111-1121
20. Girard TJ, Warren LA, Novotny WF, et al. Functional significance of the Kunitz-type inhibitory domain of lipoprotein-associated coagulation inhibition. Nature 1989;338:518-520
21. Novotny WF. Tissue factor pathway inhibitor. Semin Thromb Hemostas 1994;20:101-108
22. Lindhout T, Willems G, Blezer R, Hemker HC. Kinetics of the inhibition of human factor Xa by full length and truncated recombinent tissue factor pathway inhibitor. Biochem J 1994; 297:131-136
23. Gouin-Thibaull I, Dewar L, Craven S. Kulczycky M, Wun T-C, Ofosu FA. Possible regulation of factor VIIa-tissue factor and prothrombinase by factor Xa-TFPI and TFPI in vivo. Br J Haematol 1996;95:738-746
24. Rapaport SI, Rao LVM. The tissue factor pathway: How it has become a "Prima Ballerina." Thromb Haemostas 1995;74: 7-17
25. Lupu C, Lupu F, Dennehy U, Kakkar VV, Scully MF. Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture. Atheroscler Thromb Vasc Biol 1995; 15:2055-2062
26. Kazama Y, Komiyama Y, Kisiel W. Tissue factor pathway inhibitor and protease nexin-1 are major factor Xa binding proteins on the HepG2 cell surface. Blood 1993;8:676-682
27. Jesty J, Wun T-C, Lorenz A. Kinetics of the inhibition of factor Xa and the tissue factor-factor VIIa complex by the tissue factor pathway inhibitor in the presence and absence of heparin. Biochem J 1994;33:12686-12694
28. Lindhout T, Franssen J, Williams G. Kinetics of the inhibition of tissue-factor-factor VIIa by tissue factor pathway inhibitor. Thromb Haemostas 1995;74:910-915
29. Broze Jr GJ, Likert K, Higachi D. Inhibition of factor VIIa-tissue factor by antithrombin III and tissue factor pathway inhibitor. Blood 1993;82:1679-1680
30. Rao LVM, Rapaport SI, Hoang AD. Binding of factor VIIa to tissue factor permits rapid antithrombin III-heparin inhibition of factor VIIa. Blood 1993;81:2600-2607
31. Rao LVM, Norfany O, Hoang AD, Pendurthi UR. Mechanism of antithrombin III inhibition of factor VIIa/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity. Blood 1995;85:121-129
32. Callas DD, Hoppensteadt DA, Jeske W, et al. Comparative pharmacologic profile of a glycosaminoglycan mixture (Sulodexide) and a chemically modified heparin derivative, Suleparoide. Semin Thromb Hemostas 1993:19(Suppl 1):49-57
33. Ofosu FA, Buchanan MR. Profili farmacologici comparati dei glicosaminoglicani. Minerva Angiol 1993;18(Suppl 3a/N1): 19-23
34. Ofosu FA, Sie P, Modi GJ, et al. The inhibition of thrombin-mediated amplification reactions is critical to the expression of the anticoagulant effects of heparin. Biochem J 1987:24.3: 579-588
35. Ofosu FA, Hirsh J, Esmon CT. et al. Unfractionated heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa. Biochem J 1989;257:143-150
36. Ofosu FA, Smith LM, Anvari N, Blajchman MA. An approach to assigning in vitro potency to unfractionated and low molecular weight heparins based on the inhibition of prothrombin activation and catalyses of thrombin inhibition. Thromb Haemostas 1988;60:19.3-198
37. Ofosu FA, Lormeau JC, Craven S, Dewar L, Anvari N. Heparin and low molecular weight heparins inhibit prothrombinase formation but not its activity in plasma. Thromb Haemostas 1994;72:862-868
38. Ofosu FA, Fenton JW II, Maraganore J. et al. Inhibition of the amplification reactions of blood coagulation by site-specific inhibitors of α-thrombin. Biochem J 1992;283:893-897
39. 2C1. Biochem J 1990;272:399-406
40. Fenton II JW, Witting JI, Pouliott C, Fareed J. Thrombin anionbinding exosite interactions with heparin and various polyanions. Ann NY Acad Sci 1989;556:158-165
41. Ofosu FA, Blajchman MA, Hirsh J. The inhibition by heparin of the intrinsic pathway activation of factor X in the absence of antithrombin III. Thromb Res 1980;20:391-403
42. Sie P, Ofosu FA, Fernandez F, Buchanan MR, Petitou M, Boneu B. Respective roles of antithrombin III and heparin cofactor II in the in vitro anticoagulant effect of heparin and various sulphated polysaccharides. Br J Haematol 1986;64:707-714
43. Van Ryn-McKenna J, Ofosu FA, Hirsh J, Buchanan MR. Antithromhotic and bleeding effects of glycosaminoglycans with different degrees of sulphation. Br J Haematol 1989;71:265-269
44. Negus D, Friedgood A, Cox SJ, Peel ALG. Ultra-low dose intravenous heparin in the prevention of postoperative deep-vein thrombosis. Lancet 1980 891-894
45. Boneu B, Caranobe C, Gabaig AM, Dupony D, Sie P. Evidence for a saturable mechanism of disappearance of standard heparin in rabbits. Thromb Res 1978;46:835-844
46. Caranobe C, Boneu A, Gabaig AM, Dupony D, Sie P, Boneu B. Disappearance of circulating anti-Xa after intravenous injection of standard heparin and of a low molecular weight heparin (CY216) in normal and nephrectonised rabbits. Thromb Res 1985;40:129-133
47. Boneu B, Dol F, Caranobe C. Sie P, Honin G. Pharmacokinetics of heparin and related polysaccharides. Ann NY Acad Sci 1989;556:282-291
48. Van Rijn JLML, Trillou M, Mardiguian J, Tobelen G, Caen J. Selective binding of heparin to human endothelial cells. Implications for pharmacokinetics. Thromb Res 1987;45:211-222
49. Heibert LM, Jacques LB. Heparin uptake on the endothelium. Artery 1976;2:26-37
50. Tobelen G. Interactions between glycosaminoglycans and endothelial cells. In: Bounameaux H. ed. Low-Molecular-Weight Heparins in Prophylaxis and Therapy of Thromboembolic Diseases. New York. NY: Marcel Dekker; 1994:129-142
51. Holmer E, Kurachi K, Soderstrom G. The molecular weight dependency of the rate enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin. Biochem J 1981;193:395-100
52. Ofosu FA, Leclerc J, Delorme F, Shafai S, Frewin L, Blajchman MA. The low molecular weight Enoxaparin inhibits the consumption of factor VII and prothrombin activation in vivo associated with elective knee surgery. Br J Haemalol 1992;82: 391-399
53. Agnelli G, Iorio A, Renga C, et al. Prolonged anti-thrombin activity of low molecular weight heparins: Clinical implications for the treatment of thromboembolic disease. Circulation 1995;92: 2819-2824
54. Marchi E, Barbanti M, Milani MR, Breccia A, Fini A, Gattavecchia E. Organ glycosaminoglycan distribution after intravenous and oral administration in rats. Semin Thromb Hemostas 1994;20:297-300
55. Cristofori M, Mastacchi R, Barbanti M, Sarret M. Pharmacokinetics and distribution of a fluoreseeinated glycosaminoglycan, Sulodexide. Part I. Pharmacokinetics in rats. ArzneimForsch Drug Res 1985;35:1513-1516
56. Ruggeri A, Guizzardi S, Franchi M, Morocutti M, Mastachi R. Pharmacokinetics and distribution of a fluoresceinated glycosaminoglycan, Sulodexide, in rats. Part II. Organ distribution. Arzeim-Forsch Drug Res 1985;35:1517-1519
57. Cortelazzo S, Buchanan MR, Young E, et al. Continuous infusion of low affinity heparin and dermatan sulphate induce the release into rabbit blood of a moiety which calalyzes thrombinantithrombin III formation. Thromb Haemo Dis 1991;2: 17-23
58. Blajchman MA, Young E, Ofosu FA. The effects of unfractionated heparin, dermatan sulfate and low molecular weight heparin on vessel wall permeability in rabbits. Ann NY Acad Sci 1989;556:245-254
59. Silvestro L, Lanzarotti E, Marchi E, et al. Human pharmacokinetics of glycosaminoglycans using deuterium-labeled and unlabeled substances. Evidence for oral absorption. Semin Thromb Hemostas 1994;20:281-292
60. Breccia A, Buscutti L, Fini A. Pharmacokinetics of Sulodexide evaluated from fast moving heparin and from labelled dermatan sulfate after single intravenous and oral administration. Eur J Clin Res 1992;3:97-113
61. Milani MR, Busutti L, Brecia A, Fini A, Piani S, Marchi E. Pharmacokinetics of Sulodexide evaluated for 125I-labelled fast moving heparin after a single intravenous and oral administative of different doses in man. Bi J Clin Res 1992;3:161-178
62. Barbanti M, Aldini R, Barbara L, Simon P, Stanzani L, Mastacchi R. Efftect of Sulodexide, a heparin-like compound, on VLDL-triglyceride in the perfused rat liver. IRCS Med Sci 1985;13: 1147-1148
63. Mauro M, Ferraro G, Palmieri G. Profibrinolytic and antithrombotic effects of Sulodexide oral administration: a double-blind, cross-over placebo-controlled study. Curr Therap Res 1992;51: 342-350
64. Veriello A, Quatraro A, Ettorre E, Marchi E, Barbanti M, Giugliano D. Glycosaminoglycan administration decreases high plasma fibrinogen levels in diabetic patients. Diab Nutr Metah 1993;6:1-4
65. Lunetta M, Salanitri AT. Lowering of plasma viscosity by the oral administration of the glycusaminoglycan Sulodexide in patients with peripheral vascular disease. J Int Med Res 1992;20: 45-53
66. Ramano F, Platania M, Costa A, Salinitri T, Palazzini E. The effect of Sulodexide on blood viscosity in patients with peripheral vascular disease. Eur J Clin Res 1992;3:73-82
67. Castelluccio A, Bologna E. Eftect of Sulodexide on blood viscosity in patients with peripheral vascular disease. Curr Med Res Opinion 1991;12:325-331
68. Ceriello A, Quatraro A, Marchi E, Barbanti M, Giugliano D. Impaired fibrinolytic response to increased thrombin actization in type I diabetes mellitus: Effects of the glycosaminoglycan Sulodexide. Diabetes Metab 1993;19:225-229
69. Tiozzo R, Cinqi MR, Pietrangelo A, Albetazzi L, Calandra S, Milani MR. Effect of the heparin-like compounds on the in vitro proliferation and protein synthesis by various cell types. Arzneim-Forsch Drug Res 1989;39:15-20
70. Vijayagopal P, Ciolino HP, Radhakrisha-Murthy B, Berenson GJ. Heparin stimulates proteolglycan synthesis by vascular smooth muscle cells while suppressing cellular proliferation. Atheroselerosis 1992;94:135-146
71. Barbanti M, Guizzardi S, Calanni F, Marchi E, Babbini M. Antithrombotic and thrombolytic activity of Sulodexide in rats. Int J Clin Lab Res 1992;22:179-184
72. Caenazzo C, Garbisa S, Ceol M, et al. Heparin modulates proliferation and proteoglycan biosynthesis in murine mesangial cells: Molecular clues for its activity in nephropathy. Nephrol Dial Transplant 1995;10:175-184
73. Gambaro G, Cavazzana AO, Luzi P. et al. Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int 1992;42:285-291
74. Andriuoli G. Antihypersensitive effect of long term treatment with 3Gs (glycosaminoglycan sulphate) in spontaneously hypertensive rats. In: Atherosclerosis: Etiopathogenesis. Clinical Evaluation and Therapy. Bologna: Editrice Compositori; 1982: 465-470
75. Andriuoli G, Mastacchi R, Barbanti M. Anti-thrombotic activity of a glycosaminoglycan (Sulodexide) in rats. Thromh Res 1984;34:81-86
76. Barbanti M, Guizzardi S, Calanni F, Marchi E, Babbini M. Antithromhotic and thromholytie activity of Sulodexide in rats, Int J Clin Lab Res 1992;22:179-184
77. Lacoviello L, D'Adamo MC, Pawlak K, et al. Anti-thrombotic activity of dermatan sulphates, heparins and their combinations in an animal model of arterial thrombosis. Thromb Haemostas 1996;76:1102-1107
78. Tarugi P, Tiozzo-Costa R, Barbanti M, Calandra S, Mastacchi R. Effects of Sulodexide. a heparin-like compound, on experimental atherosclerosis in the rabbit. Mol Sci Res 1987;15:1071-1072
79. Buchanan MR, Liao P, Smith LJ. Ofosu FA. Prevention of thrombus formation and growth by anti-thrombin III- and heparin cofactor II-dependent thrombin inhibitors: importance of heparin cofactor II. Thromb Res 1994;74:463-475
80. Okwusidi J, Falcone M, Van Ryn-McKenna J, Hirsh J, Ofosu FA, Buchanan MR. In vivo catalysis of thrombin inhibition by antithrombin III or heparin cofactor II and anti-thrombotic effect: differential effects of unfractionated heparin and dermatan sulfate. Thromb Haemorrh Dis 1990;1/2:77-80
81. Pejana E, Villa S, De Gaetano G. Bleeding time in rats: A comparison of different experimental conditions. Thromb Haemostas 1982;48:108-111